| 2026-10-26 16:44 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Clinical trial results update; no M&A, activist, or strategic transaction signals present. |
SEC · detail |
| 2026-10-14 16:01 |
8-K |
["5.02"] |
officer change |
0.15
|
CMO departure with standard notice period; no M&A indicators present in filing. |
SEC · detail |
| 2026-09-23 16:01 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Clinical trial failure announcement; no M&A signals present. |
SEC · detail |
| 2026-09-14 16:13 |
8-K |
["8.01"] |
other |
0.05
|
Nasdaq compliance notification regarding minimum bid price requirement regained—no M&A signal. |
SEC · detail |
| 2026-08-24 16:15 |
8-K |
["5.03", "7.01"] |
other |
0.05
|
Reverse stock split (1:10) announcement; routine corporate action with no M&A implications. |
SEC · detail |
| 2026-08-19 16:13 |
8-K |
["5.02", "9.01"] |
officer change |
0.35
|
CFO appointment with strong M&A/capital markets experience; weak indirect signal without explicit strategic review or transaction language. |
SEC · detail |
| 2026-08-12 16:14 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement; no M&A signals present in 8-K items 2.02 and 9.01. |
SEC · detail |
| 2026-07-29 16:01 |
8-K |
["8.01"] |
other |
0.05
|
Routine audit committee reconstitution to restore Nasdaq compliance; no M&A signal. |
SEC · detail |
| 2026-07-14 17:19 |
8-K |
["5.02"] |
officer change |
0.35
|
CEO employment agreement revised with improved terms; change-of-control severance provisions suggest M&A contingency planning. |
SEC · detail |
| 2026-07-08 16:06 |
8-K |
["5.02"] |
other |
0.05
|
Executive compensation award for financing transaction completion; no M&A indicators present. |
SEC · detail |
| 2026-07-06 16:30 |
8-K |
["5.02", "5.03", "5.07"] |
officer change |
0.32
|
CFO departure and board appointment with authorized share increase; weak M&A signals, likely routine corporate governance. |
SEC · detail |
| 2026-06-05 16:01 |
8-K |
["5.02"] |
officer change |
0.35
|
CFO departure to pursue board/professional opportunities; weak M&A signal absent strategic context. |
SEC · detail |
| 2026-05-13 16:14 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement with no M&A-related content or signals. |
SEC · detail |
| 2026-05-08 16:20 |
8-K |
["8.01"] |
other |
0.05
|
FDA meeting update on HLHS clinical trial; no M&A signals present. |
SEC · detail |